124 related articles for article (PubMed ID: 26698294)
1. Epigenetic modifiers: basic understanding and clinical development.
Piekarz RL; Bates SE
Clin Cancer Res; 2009 Jun; 15(12):3918-26. PubMed ID: 19509169
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy in urologic cancers: an update on clinical trials.
Faleiro I; Leão R; Binnie A; de Mello RA; Maia AT; Castelo-Branco P
Oncotarget; 2017 Feb; 8(7):12484-12500. PubMed ID: 28036257
[TBL] [Abstract][Full Text] [Related]
3. When less is more-reducing complexity in cancer trials.
Patel TH; Rivera DR; Singh H; Kluetz PG
Lancet Oncol; 2024 Jan; 25(1):10-12. PubMed ID: 38181803
[No Abstract] [Full Text] [Related]
4. DNA methylation at enhancer regions: Novel avenues for epigenetic biomarker development.
Clermont PL; Parolia A; Liu HH; Helgason CD
Front Biosci (Landmark Ed); 2016 Jan; 21(2):430-46. PubMed ID: 26709784
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic alternations and cancer chemotherapy response.
Lv JF; Hu L; Zhuo W; Zhang CM; Zhou HH; Fan L
Cancer Chemother Pharmacol; 2016 Apr; 77(4):673-84. PubMed ID: 26707728
[TBL] [Abstract][Full Text] [Related]
6. The role of DNA methylation in the pathogenesis of disease: what can epigenome-wide association studies tell?
Ek WE; Rask-Andersen M; Johansson Å
Epigenomics; 2016 Jan; 8(1):5-7. PubMed ID: 26698830
[No Abstract] [Full Text] [Related]
7. Epidrugs: targeting epigenetic marks in cancer treatment.
Miranda Furtado CL; Dos Santos Luciano MC; Silva Santos RD; Furtado GP; Moraes MO; Pessoa C
Epigenetics; 2019 Dec; 14(12):1164-1176. PubMed ID: 31282279
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer.
Chen M; Nie J; Liu Y; Li X; Zhang Y; Brock MV; Feng K; Wu Z; Li X; Shi L; Li S; Guo M; Mei Q; Han W
Int J Cancer; 2018 Sep; 143(6):1530-1540. PubMed ID: 29663379
[TBL] [Abstract][Full Text] [Related]
9. Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.
Chalakur-Ramireddy NKR; Pakala SB
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29298879
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Targets and their Inhibitors in Cancer Therapy.
Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic inhibitors.
Verma M; Banerjee HN
Methods Mol Biol; 2015; 1238():469-85. PubMed ID: 25421675
[TBL] [Abstract][Full Text] [Related]
12. The failure of epigenetic combination therapy for cancer and what it might be telling us about DNA methylation inhibitors.
Yang AS; Yang BJ
Epigenomics; 2016 Jan; 8(1):9-12. PubMed ID: 26698294
[No Abstract] [Full Text] [Related]
13. Epigenetic drugs take on cancer.
Kaiser J
Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
[No Abstract] [Full Text] [Related]
14. Epigenetic therapies reach main street.
Bates SE
Clin Cancer Res; 2009 Jun; 15(12):3917. PubMed ID: 19528089
[No Abstract] [Full Text] [Related]
15. Epigenetic therapy for solid tumors: from bench science to clinical trials.
Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
